Exocrine pancreatic enzyme deficiency as in cystic fibrosis, chronic pancreatitis, post pancreatectomy, post gastro-intestinal bypass surgery (eg Billroth II gastroenterostomy), and ductal obstruction from neoplasm (eg of the pancreas or common bile duct).
After an overview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatric and adult treatment approaches.
This review gives a comprehensive overview on HL addressing epidemiology, pathophysiology and current treatment options as well as recent developments and perspectives.
Background: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis.
The China National Medical Products Administration (NMPA) has approved KeChow Pharma’s tunlametinib (HL 085) for treating patients with neuroblastoma ras viral oncogene homolog (NRAS) mutated advanced melanoma.
This updated guideline focuses on the clinical management of adult patients with a diagnosis of classical Hodgkin lymphoma (HL).
The 2018 ESMO Clinical Practice Guidelines on Hodgkin lymphoma (HL) are based on results from recent studies and analyses.
Seattle Genetics, Inc. has announced that the FDA has accepted for filing a supplement to the Biologics License Application (sBLA)...
Seattle Genetics, Inc.announced the publication of data from the ECHELON-1 phase III clinical trial online in the journal Clinical Cancer...
Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation.